Showing results (71-80 of 333) with videos related to
Sort By:
Pageof 34
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|October 12, 2025
Clinical characteristics and risk factors for severe disease among hospitalized patients with COVID-19 in Japan after cessation of public funding: A single-center retrospective study in 2024-2025Chie Yamamoto, Yoko Nukui, Yuta Nakagawa, et al.Scientific Reports|February 8, 2020
Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysisYuko Kanbayashi, Takeshi Ishikawa, Yusuke Tabuchi, et al.Medicine|June 8, 2018
Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatmentJunji Uchino, Akira Nakao, Nobuyo Tamiya, et al.Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|November 12, 2010
[A case of non-small cell lung cancer with hemodialysis which responded to docetaxel monotherapy]Yumiko Abe, Kentaro Tanaka, Koichiro Matsumoto, et al.Internal Medicine (Tokyo, Japan)|February 16, 2013
Hypoalbuminemia and lymphocytopenia are predictive risk factors for in-hospital mortality in patients with tuberculosisKyoko Okamura, Nobuhiko Nagata, Kentaro Wakamatsu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 30, 2013
Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by α1 nicotinic acetylcholine receptor-mediated activation in PC9 cellsShuo Wang, Koichi Takayama, Kentaro Tanaka, et al.Clinical Lung Cancer|March 26, 2019
Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study)Osamu Hiranuma, Junji Uchino, Tadaaki Yamada, et al.Asia-Pacific Journal of Oncology Nursing|October 2, 2018
Promotion of Behavioral Change and the Impact on Quality of Life in Elderly Patients with Advanced Cancer: A Physical Activity Intervention of the Multimodal Nutrition and Exercise Treatment for Advanced Cancer ProgramTakako Mouri, Tateaki Naito, Ayumu Morikawa, et al.Lung Cancer (Amsterdam, Netherlands)|April 4, 2015
Successful treatment with alectinib after crizotinib-induced esophageal ulcerationYasuto Yoneshima, Isamu Okamoto, Tomotsugu Takano, et al.Cancer Chemotherapy and Pharmacology|October 7, 2016
Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancerMasato Fukae, Yoshimasa Shiraishi, Takeshi Hirota, et al.Pageof 34